About this trial
The purpose of this trial is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Patient Profile
Where’s this trial being run?
Beaumont Hospital and St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK-7684A-010/KEYVIBE-010 |
|---|---|
| Number: | 22-28 |
| Full Title: | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010) |
| Principal Investigator: | To be confirmed |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MSD |
| Recruitment Started: |
Global: June 2023 Ireland: Q4 2023 |
| Global Recruitment Target: | Not Specified |
|---|---|
| Ireland Recruitment Target: | 8 |